Investor Relations

SciClone is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN(R) (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and ... More »

Aug 9, 2010 at 4:30 PM ET
Q2 2010 SciClone Pharmaceuticals, Inc. Earnings Conference Call

View all events & presentations »

 Corporate Presentation

SciClone seeks out China deals (San Francisco Business Times)

Recent Releases

Jul 26, 2010
SciClone Pharmaceuticals to Report Second Quarter 2010 Financial Results and Provide a Business Update on August 9

Jun 30, 2010
SciClone and Sigma-Tau Announce Final Data From Clinical Trial of ZADAXIN as H1N1 Vaccine Enhancer

View all releases »

Events & Presentations

Aug 18, 2010
ImVacs Adjuvants and Delivery Systems

Aug 9, 2010 at 4:30 PM ET
Q2 2010 SciClone Pharmaceuticals, Inc. Earnings Conference Call

View all events & presentations »